A guide through the regulations The management of disruptive behavioral symptoms (DBS) in long-term care patients may ...
Pharmagenesis, Inc., a research and development company based in Palo Alto developing anti-cancer therapies, has sign...
TABLE 1 Hepatitis B and C: Indications and Treatment Recommended treatme...
Connetics Corporation announced FDA approval of Evoclin (formerly known as Actiza) clindamycin 1% foam for once-daily ...
[FIGURE 1 OMITTED]
CRANBURY, N.J. -- Valera Pharmaceuticals today announced that it has initiated patient enrollment for a pivotal Phase III trial of a one-year implant for the hormonal treatment of central precocious puberty (CPP), an affliction characterized by the early onset of sexual development in preadolescents.